44 results about "Pulmonary inhalation" patented technology

Hypertonic sugar compositions administered by other than ingestion and swallowing or intravascular injection, such as by intranasal spray or drops, intraocular drops or ointment, oral spray, intraotic spray or drops, lozenges, chewable tablet, chewing gum, or gargle, pulmonary inhalation, vaginal or rectal suppositories, or transdermal creams, ointments, lotions, or patches, are effective to open the blood-brain barrier to permit entry into the central nervous system of a co-administered chemical compound, such as a nutrient or a therapeutic or diagnostic agent. In this way, the compositions and methods of the invention increase the therapeutic or diagnostic efficacy of such chemical compounds.

The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

The invention provides a pyrazolopyrimidine compound shown as a structural formula (I), a pharmaceutical composition taking the pyrazolopyrimidine compound as an active component, a preparation method of the pyrazolopyrimidine compound and the pharmaceutical composition as well as an application of the pyrazolopyrimidine compound and the pharmaceutical composition in preparation of a TRPC6 (Transient Receptor Potential Channel 6) adjustor probe medicine and related medicines for preventing and treating glomerulopathy and myocardial hypertrophy. The pyrazolopyrimidine compound and derivatives provided by the invention can be used to prepare medical preparations in various forms which comprise oral liquids, injections, pulmonary inhalation preparations and transdermal preparations, specifically injections, oral liquids, troches, capsules, granules, aerosols, dry powder inhalation, patches and the like.

The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It also relates to methods for producing particles suitable for pulmonary inhalation, such as spray drying or jet milling.

The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts of fentanyl in a shorter time and at lower dose levels of administered fentanyl when compared to fentanyl administered by an oral transmucosal route.

The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.

The present invention relates to inhalable formulations of apomorphine or its pharmaceutically acceptable salts or esters for use in treating sexual dysfunction. The present invention also relates to methods for preparing the apomorphine formulations as well as to methods for treatment of sexual dysfunction using said formulations and inhalers including said formulations. The present invention further relates to the use of apomorphine in the manufacture of a medicament for treating sexual dysfunction.

The invention relates to a phospholipid chitosan drug delivery system, a preparation method and uses thereof, wherein the phospholipid chitosan drug delivery system comprises a drug-lipid complex and chitosan, the phospholipid in the phospholipid chitosan drug delivery system is derived from free phospholipid and/or the phospholipid in a lipid complex, and the drug in the drug-lipid complex does not contain insulin. The drug delivery system of the present invention can be used for oral administration systems, transdermal administration systems, mucosal administration systems, pulmonary inhalation administration systems and other administration systems.

The invention relates to proanthocyanidin sustained release nano-micro spheres. The proanthocyanidin sustained release nano-micro spheres comprise 1-5 parts of proanthocyanidin, 1-12 parts of chitosan or derivatives thereof, 1-12 parts of phospholipid or derivatives thereof and 1-10 parts of excipients, wherein the chitosan and the derivatives thereof are one or more of high, medium and low-molecular weight chitosan, chitosan oligosaccharide, chitosan quaternary ammonium salt and carboxymethyl chitosan. The particle size of the proanthocyanidin sustained release nano-micro spheres is 10nm-0.3 mu m; the proanthocyanidin is prepared into the powder sustained release nano-micro spheres, and the proanthocyanidin sustained release nano-micro spheres can directly play a role in the lung as a pulmonary inhalation medicine-carrying formulation, improve the bioavailability of the proanthocyanidin and reduce the dosage by sustained release; the proanthocyanidin nano-micro spheres can also be applied as an oral sustained release formulation; the proanthocyanidin nano-micro spheres have appropriate particle size and morphology and other powder properties, as well as sustained release; furthermore, the preparation method has the advantages of simplicity and convenience in operation, stable process and easiness in industrial production.

The present invention provides novel processes and methodologies to minimize the bitter or otherwise unpleasant taste, to minimize the tendency to stimulate the cough reflex, or to minimize oropharyngeal deposition of medically-active compounds administered by the pulmonary/inhalation route and to deliver hydroxychloroquine (HCQ) either singularly or in combination with an antimalarial and aminoquinolone by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the bitter or otherwise unpleasant taste of HCQ or any potential to stimulate the cough reflex, and to deliver a dopaminergic compound or its prodrug, including ABT-431 by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate the cough reflex, and to deliver a lantibiotic, including duramycin by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate throat irritation.

The present invention discloses pulmonary inhalation curcumin-phospholipid complex chitosan microspheres and a preparation method thereof, wherein the pulmonary inhalation curcumin-phospholipid complex chitosan microspheres comprise, by weight, 1 part of a curcumin compound, 2-4 parts of phospholipid, and 4-10 parts of chitosan, and are prepared by using a spray-drying method. According to the present invention, the microspheres have good dispersion property, do not have significant aggregation and other phenomena, have the particle size of 1-10 [mu]m, and are suitable for the dry powder inhalation agent so as to achieve the pulmonary administration purpose, wherein the effective site deposition rate determined by a two-stage glass impactor is 20-60%.

The invention belongs to the field of medicine, and relates to a drug for treating acute lung injury and acute respiratory distress syndrome, wherein the active components of the drug is ganolucidic acid A or corosolic acid or a composition of ganolucidic acid A and corosolic acid, and the dosage form of the drug is one selected from an oral liquid preparation, a pulmonary inhalation preparation and an injection. According to the present invention, the drug can reduce the pulmonary edema of acute lung injury and acute respiratory distress syndrome, reduce lung hyaline membrane formation and other lung lesions, and easily improve the symptoms of acute lung injury and acute respiratory distress syndrome.

The invention relates to application of 3-(3,4-dihydroxycinnamoyl) quinic acid to the preparation of medicines and functional food for protecting an ovarian function, promoting ovulation and treating ovulation disorder. The 3-(3,4-dihydroxycinnamoyl) quinic acid can be prepared into medicinal preparations of various forms which comprise oral administration, injection and pulmonary inhalation preparations and transdermal preparations and particularly comprise injections, oral liquid, tablets, capsules, granules, aerosols, powder aerosols, pressurized sprays, patches and the like.

The invention provides benzimidazole and a derivative thereof, a medicinal composition which contains the benzimidazole and derivative thereof as active components and is used for preventing and treating neurological and psychotic diseases, and application thereof in preparation of medicaments and functional foods for resisting senility, senile dementia and other neurological and psychotic diseases. The benzimidazole and derivative thereof provided by the invention can be prepared into pharmaceutical preparations of various forms, including oral administration, injection, lung inhalation and transdermal preparations, and specifically including injections, oral liquids, tablets, capsules, granules, aerosols, dry powder inhalers, sprays, plasters and the like.

The invention discloses insulin flexible particles and a preparation thereof. The insulin flexible particles contain an insulin/phospholipid composite and an ionic surfactant and are vesicles of circular or oval structures, the particle size is 5000nm or below, and the drug encapsulation rate is 60 percent or above. The insulin flexible particles of the invention can further contain a nonionic surfactant, free phospholipid or cholesterol. The insulin flexible particles of the invention differ in composition from insulin contained vesicles or flexible vesicles reported in the prior literatures,is also different from novel insulin contained nanovesicles as reported in the prior literatures, thus having better flexibility and higher transmucosal transport capacity. The insulin flexible particles of the invention can be prepared into clinically acceptable dosage forms by being added with an excipient for insulin parenteral administration delivery including intranasal administration, oraladministration, transdermal administration and pulmonary inhalation.

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The invention relates to a medicine for treating bronchial asthma in children. The medicine is characterized by containing salbutamol, budesonide and soybean lecithin. By reasonably designing the formula, the medicine for treating children bronchial asthma has the advantages of being good in stability and uniform in particle size, and particle size distribution and average particle size both meetthe requirements of pulmonary inhalation preparations.

The invention relates to an integrated device and method for improving pulmonary inhalation medication through lactose micropowder pre-deposition, wherein the integrated device mainly comprises an inhaler, a head and throat part, a respiratory pipeline model device and a lung model device; the inhaler comprises two modes of pre-deposition lactose administration and normal administration; and the respiratory pipeline model device can simulate the real environment of a human body by wetting the pipe wall during measurement. According to the novel administration method, a lactose micro-powder pre-deposition step is arranged one minute before prior inhalation administration, and 20-200 milligrams of anhydrous lactose micro-powder such as flower-shaped lactose, amorphous coated lactose and thelike are pre-deposited in the moist and viscous head and throat part, the respiratory pipeline and part of a lung trachea, so that a smooth inhalation environment is provided for the inhalation of subsequent medicinal powder, and the deposition rate of the medicinal powder in a target area of the lung trachea is improved by 30-200%.

The invention provides a method for preparing a dry powder inhaler, which comprises dispersing active ingredients in a carrier through a specific mixing method, wherein the specific mixing method is extrusion shear mixing. The dry powder inhaler is prepared by the method provided by the invention, the particles of the active ingredient are not easily crushed during the mixing process, and the prepared dry powder inhaler has suitable aerodynamic fine particles when it is administered to the lungs through a dry powder inhalation device Fraction (FPF) and good content uniformity, excellent inhalation characteristics and other characteristics.